Specific protection against breast cancers by cyclin D1 ablation
- PMID: 11429595
- DOI: 10.1038/35082500
Specific protection against breast cancers by cyclin D1 ablation
Abstract
Breast cancer is the most common malignancy among women. Most of these cancers overexpress cyclin D1, a component of the core cell-cycle machinery. We previously generated mice lacking cyclin D1 using gene targeting. Here we report that these cyclin D1-deficient mice are resistant to breast cancers induced by the neu and ras oncogenes. However, animals lacking cyclin D1 remain fully sensitive to other oncogenic pathways of the mammary epithelium, such as those driven by c-myc or Wnt-1. Our analyses revealed that, in mammary epithelial cells, the Neu-Ras pathway is connected to the cell-cycle machinery by cyclin D1, explaining the absolute dependency on cyclin D1 for malignant transformation in this tissue. Our results suggest that an anti-cyclin D1 therapy might be highly specific in treating human breast cancers with activated Neu-Ras pathways.
Comment in
-
Are all cancer genes equal?Nature. 2001 Jun 28;411(6841):1001-2. doi: 10.1038/35082655. Nature. 2001. PMID: 11429580 No abstract available.
Similar articles
-
Are all cancer genes equal?Nature. 2001 Jun 28;411(6841):1001-2. doi: 10.1038/35082655. Nature. 2001. PMID: 11429580 No abstract available.
-
Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E.Oncogene. 2002 Jan 10;21(2):291-8. doi: 10.1038/sj.onc.1205025. Oncogene. 2002. PMID: 11803472
-
The reciprocal dance between cancer and development.N Engl J Med. 2002 Jul 11;347(2):134-6. doi: 10.1056/NEJMcibr020712. N Engl J Med. 2002. PMID: 12110743 Review. No abstract available.
-
The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.Cancer Res. 2003 Jun 15;63(12):3395-402. Cancer Res. 2003. PMID: 12810676
-
Control of the three-dimensional growth pattern of mammary epithelium: role of genes of the Wnt and erbB families studied using reconstituted epithelium.Biochem Soc Symp. 1998;63:21-34. Biochem Soc Symp. 1998. PMID: 9513708 Review.
Cited by
-
MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches.Oncogene. 2013 Feb 28;32(9):1073-81. doi: 10.1038/onc.2012.158. Epub 2012 May 14. Oncogene. 2013. PMID: 22580612 Free PMC article. Review.
-
Cyclins and cell cycle control in cancer and disease.Genes Cancer. 2012 Nov;3(11-12):649-57. doi: 10.1177/1947601913479022. Genes Cancer. 2012. PMID: 23634253 Free PMC article.
-
Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1.Oncotarget. 2016 Jun 14;7(24):35960-35978. doi: 10.18632/oncotarget.8482. Oncotarget. 2016. PMID: 27166267 Free PMC article.
-
Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer.Front Pharmacol. 2024 Jan 30;14:1332539. doi: 10.3389/fphar.2023.1332539. eCollection 2023. Front Pharmacol. 2024. PMID: 38352694 Free PMC article. Review.
-
Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells.EMBO Rep. 2003 Feb;4(2):166-71. doi: 10.1038/sj.embor.embor735. EMBO Rep. 2003. PMID: 12612606 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous